Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 103Leukemia 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Leukemia, Monocytic, Acute 26Leukemia, Erythroblastic, Acute 23Congenital Abnormalities 23Leukemia, Myelomonocytic, Acute 22Leukemia, Megakaryoblastic, Acute 21Myelodysplastic Syndromes 17Lymphoma 12Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 10Leukemia, Biphenotypic, Acute 9Lymphoma, Non-Hodgkin 6Burkitt Lymphoma 6Anemia, Refractory, with Excess of Blasts 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Promyelocytic, Acute 5Blast Crisis 5Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Leukemia, Basophilic, Acute 4Sarcoma, Myeloid 3Neutropenia 3Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3

Interventions

Cytarabine 2venetoclax 1pembrolizumab 1obinutuzumab 1neratinib 1idelalisib 1ibrutinib 1gilteritinib 1Surveys and Questionnaires 1Positron Emission Tomography Computed Tomography 1Mitoxantrone 1Interleukin-15 1Gemtuzumab 1Daunorubicin 1CPX-351 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Mitoxantrone × Other hematologic neoplasm × Clear all
NCT00143975 2010-08-12

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

University of Ulm

Phase 2 Completed
95 enrolled
Other hematologic neoplasm

Disease, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡